Indium (111in) Dtpa Curium

Indium-111 pentetate, the active ingredient in Indium (111in) Dtpa Curium, is a radiopharmaceutical presented as a sterile solution for intrathecal use. It is employed in diagnostic imaging to assess cerebrospinal fluid dynamics and related neurological conditions in patients undergoing clinical evaluation.

GNH USA supplies Indium (111in) Dtpa Curium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic centres, and research institutions worldwide, with rigorous quality assurance and regulatory compliance. Our distribution network ensures timely delivery and support for clinical imaging programs.

Indium-111 pentetate is used in diagnostic radiology to evaluate cerebrospinal fluid pathways and related conditions.

- Cerebrospinal fluid (CSF) flow studies: enables visualization of CSF dynamics to detect blockages or leaks. - Spinal canal imaging: assists in identifying CSF leaks or abnormal collections along the spinal axis. - Ventricular shunt patency testing: assesses functional status of implanted shunt systems in hydrocephalus patients. - Post‑surgical CSF monitoring: evaluates CSF distribution after neurosurgical procedures to confirm proper drainage.

Adverse reactions may occur following intrathecal administration of Indium-111 pentetate.

Common Side Effects: - Headache: mild to moderate discomfort occurring shortly after injection. - Nausea or vomiting: transient gastrointestinal upset. - Injection site pain: localized soreness at the lumbar puncture site. - Transient flushing or warmth: brief sensation of heat. - Dizziness or light‑headedness: usually resolves within minutes. - Low‑grade fever: mild temperature elevation.

Serious or Rare Side Effects: - Allergic reaction: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Radiation‑induced tissue injury: localized damage to neural tissue in rare cases. - Severe hypotension: sudden drop in blood pressure post‑procedure. - Seizures: uncommon neurologic event. - Infection at injection site: meningitis or cellulitis. - Radiation myelopathy: delayed spinal cord injury from high cumulative exposure.

Prior to use, clinicians should evaluate patient‑specific factors and follow handling guidelines.

- Pregnancy: avoid unless essential, as fetal radiation exposure cannot be excluded. - Breastfeeding: discontinue nursing for an appropriate period after administration. - Renal impairment: monitor because clearance of the chelate may be reduced. - Prior allergic reactions to DTPA or radiopharmaceuticals: assess risk before administration. - Concomitant use of other intrathecal agents: ensure compatibility to prevent adverse interactions. - Store at ambient temperature: keep in original shielding container, protect from light, and do not freeze.

Indium-111 pentetate may interact with other agents that affect imaging quality or patient safety.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: may cause image overlap and inaccurate interpretation. - High‑dose iodinated contrast agents: can alter radionuclide distribution and imaging results. - Myelosuppressive chemotherapy: increases risk of radiation‑related bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: observe for bleeding at the lumbar puncture site. - Beta‑blockers: may mask tachycardia response to adverse events. - Renal‑clearing drugs: adjust monitoring as renal excretion of the chelate may be affected. - CNS depressants: watch for additive sedation or dizziness.